You might also like
QuidelOrtho Corporation (QDEL) is a global leader in in vitro diagnostics, specializing in developing and manufacturing intelligent solutions that transform data into actionable insights. The company provides fast, accurate, and reliable diagnostic testing solutions across various settings, including physician offices, hospitals, clinical laboratories, and retail clinics. Its offerings include immunoassay and molecular testing, clinical chemistry, transfusion medicine, and over-the-counter diagnostic products.
- Labs - Develops and supplies diagnostic solutions for clinical laboratories, focusing on immunoassay and molecular testing.
- Transfusion Medicine - Offers products for immunohematology and donor screening, supporting blood banks and donor centers.
- Point of Care - Provides rapid diagnostic testing solutions for use in physician offices, urgent care clinics, and retail clinics.
- Molecular Diagnostics - Delivers advanced molecular testing solutions for specialized diagnostic needs.
- Non-Core Revenue - Includes contract manufacturing and business collaborations to support diagnostic operations.
- Given the current tariff mitigation strategies, how does management plan to adjust if a larger percentage of shipments, especially subcomponent materials, begin facing tariffs in the future?
- With most immunoassay manufacturing concentrated in the U.K. while U.S. capacity remains limited, how does management intend to diversify production risks amid potential global trade disruptions?
- As COVID testing revenues decline and flu/combo test revenue remains durable, does management foresee a permanent shift in product mix, and what impact might that have on future revenue projections?
- Although Q1 cost savings initiatives delivered improved EBITDA margins, what are the risks that ongoing macroeconomic pressures and supply chain shifts could erode these margins in subsequent quarters?
- As you approach the FDA submission for the Savanna respiratory panel, what contingency plans are in place if regulatory timelines are extended or additional compliance challenges emerge?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
This competitor is one of the global companies with which the company competes in the development and marketing of in vitro diagnostic (IVD) products. It has substantially greater financial, marketing, and other resources than the company. | |
Roche | This competitor is a significant player in the IVD market and competes with the company in areas such as product performance, price, and market reach. |
This competitor is mentioned as one of the multinational companies investing in competing technologies, products, and services in the diagnostics market. | |
This competitor is highlighted as a large multinational company with competitive advantages in financial, technical, and marketing resources. | |
Siemens Healthineers | This competitor is noted for its presence in the diagnostics market and its ability to compete on factors such as price and product performance. |
This competitor is identified as one of the companies competing in the IVD market, particularly in specialized diagnostic technologies. | |
This competitor is mentioned as a significant player in the diagnostics market, competing on innovation and product offerings. | |
This competitor is recognized for its investments in diagnostic technologies and its competitive presence in the market. | |
This competitor is noted for its focus on molecular diagnostics and its competition with the company in this segment. | |
This competitor is highlighted as a multinational company with substantial resources and a strong presence in the diagnostics market. | |
bioMérieux | This competitor is mentioned as a significant player in the diagnostics market, competing on factors such as product performance and innovation. |
Revitty | This competitor is identified as one of the companies competing in the diagnostics market, particularly in specialized diagnostic technologies. |
Recent press releases and 8-K filings for QDEL.
- The company held its annual meeting on May 20, 2025 where key proposals were presented, including board director elections and other governance matters.
- Stockholders approved the Second Amended and Restated 2018 Equity Incentive Plan, increasing share availability and extending its term to May 20, 2035, as confirmed by proxy vote outcomes.
- Final voting results also ratified the appointment of KPMG LLP as the independent auditor for the 2025 fiscal year and elected 11 board members.